(19)
(11) EP 3 013 824 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.11.2018 Bulletin 2018/47

(45) Mention of the grant of the patent:
16.05.2018 Bulletin 2018/20

(21) Application number: 14733220.9

(22) Date of filing: 27.06.2014
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61K 31/437(2006.01)
 C07D 491/048(2006.01)
A61P 25/28(2006.01)
(86) International application number:
PCT/EP2014/063771
(87) International publication number:
WO 2014/207240 (31.12.2014 Gazette 2014/53)

(54)

CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

CARBOLIN-VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG NEURODEGENERATIVER ERKRANKUNGEN

COMPOSÉS CARBOLINE UTILISABLES DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.06.2013 EP 13305927
28.06.2013 EP 13305928

(43) Date of publication of application:
04.05.2016 Bulletin 2016/18

(73) Proprietors:
  • Alzprotect
    59120 Loos (FR)
  • Université de Lille
    59800 Lille (FR)
  • INSERM - Institut National de la Santé et de la Recherche Médicale
    75013 Paris (FR)

(72) Inventors:
  • MELNYK, Patricia
    F-59112 Annoeullin (FR)
  • CARATO, Pascal
    86170 Neuville de Poitou (FR)
  • BURLET, Stéphane
    F-59170 Croix (FR)
  • NGUYEN, Emilie
    F-72000 Le Mans (FR)
  • VERWAERDE, Philippe
    F-59211 Santes (FR)
  • SERGEANT, Nicolas
    F-59790 Ronchin (FR)
  • ESTRELLA, Cécilia
    F-59160 Lomme (FR)

(74) Representative: Cabinet Plasseraud 
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09
75440 Paris Cedex 09 (FR)


(56) References cited: : 
WO-A1-2006/051489
WO-A2-2009/003003
 WO-A1-2013/062344
US-A- 4 663 456
   
  • AKSANOVA L A ET AL: "PREPARATION AND PHARMACOLOGICAL EXAMINATION OF A NUMBER OF DERIVATIVES OF TETRAHYDROBENZOFUROPYRIDINE", PHARMACEUTICAL CHEMISTRY JOURNAL, SPRINGER NEW YORK LLC, US, vol. 9, no. 1, 1 January 1975 (1975-01-01) , pages 5-07, XP001119253, ISSN: 0091-150X, DOI: 10.1007/BF01145653
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).